JP2012191939A5 - - Google Patents

Download PDF

Info

Publication number
JP2012191939A5
JP2012191939A5 JP2012129374A JP2012129374A JP2012191939A5 JP 2012191939 A5 JP2012191939 A5 JP 2012191939A5 JP 2012129374 A JP2012129374 A JP 2012129374A JP 2012129374 A JP2012129374 A JP 2012129374A JP 2012191939 A5 JP2012191939 A5 JP 2012191939A5
Authority
JP
Japan
Prior art keywords
seq
oligonucleotide
heg
immune response
ggttgt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012129374A
Other languages
English (en)
Japanese (ja)
Other versions
JP5775024B2 (ja
JP2012191939A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012191939A publication Critical patent/JP2012191939A/ja
Publication of JP2012191939A5 publication Critical patent/JP2012191939A5/ja
Application granted granted Critical
Publication of JP5775024B2 publication Critical patent/JP5775024B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2012129374A 2004-09-01 2012-06-06 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 Expired - Fee Related JP5775024B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60683304P 2004-09-01 2004-09-01
US60/606,833 2004-09-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007530180A Division JP2008514187A (ja) 2004-09-01 2005-08-24 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物

Publications (3)

Publication Number Publication Date
JP2012191939A JP2012191939A (ja) 2012-10-11
JP2012191939A5 true JP2012191939A5 (enExample) 2013-01-24
JP5775024B2 JP5775024B2 (ja) 2015-09-09

Family

ID=36036819

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007530180A Pending JP2008514187A (ja) 2004-09-01 2005-08-24 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
JP2012129374A Expired - Fee Related JP5775024B2 (ja) 2004-09-01 2012-06-06 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007530180A Pending JP2008514187A (ja) 2004-09-01 2005-08-24 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物

Country Status (14)

Country Link
US (2) US8759305B2 (enExample)
EP (2) EP1794174B1 (enExample)
JP (2) JP2008514187A (enExample)
KR (1) KR101268877B1 (enExample)
CN (1) CN101052643B (enExample)
AU (2) AU2005282889B2 (enExample)
CA (1) CA2578775C (enExample)
DK (1) DK1794174T3 (enExample)
ES (2) ES2385657T3 (enExample)
NZ (1) NZ553581A (enExample)
PL (1) PL1794174T3 (enExample)
PT (1) PT1794174E (enExample)
SI (1) SI1794174T1 (enExample)
WO (1) WO2006028742A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514187A (ja) 2004-09-01 2008-05-08 ダイナバックス テクノロジーズ コーポレイション 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
CA2591582A1 (en) * 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
DE102005005642A1 (de) * 2005-02-06 2006-08-10 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Nukleinsäuren, die zur Ausbildung von stem-loop-Sekundärstrukturen geeignete Sequenzen umfassen
CN101171033A (zh) 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗:其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
AU2006266503B2 (en) 2005-07-01 2011-12-08 Index Pharmaceuticals Ab Immunostimulatory method
ATE439135T1 (de) 2005-07-01 2009-08-15 Index Pharmaceuticals Ab Modulierung der reaktion auf steroide
EP2982679A1 (en) 2005-10-12 2016-02-10 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
AU2006306805A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
JP2010536787A (ja) * 2007-08-15 2010-12-02 イデラ ファーマシューティカルズ インコーポレイテッド Toll様受容体モジュレータ
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
US8030289B2 (en) 2008-08-06 2011-10-04 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
ES2478012T3 (es) * 2008-08-06 2014-07-18 Changchun Huapu Biotechnology Co., Ltd. Oligonucleótidos y uso de los mismos
WO2010042543A2 (en) * 2008-10-06 2010-04-15 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
EP2451974A2 (en) * 2009-07-08 2012-05-16 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
EP2582398B1 (en) 2010-06-16 2016-04-13 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
JP5921535B2 (ja) * 2010-06-16 2016-05-24 ディナバックス テクノロジーズ コーポレイション Tlr7および/またはtlr9阻害剤を用いる治療の方法
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
JP5813778B2 (ja) 2010-11-19 2015-11-17 イデラ ファーマシューティカルズ インコーポレイテッドIdera Pharmaceuticals, Inc. トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド(iro)化合物
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
EP2754714A1 (en) * 2013-01-14 2014-07-16 Sarepta Therapeutics, Inc. Inhibitory oligonucleotides and their use in therapy
MA50829A (fr) 2015-06-01 2018-04-11 Sarepta Therapeutics Inc Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
JP7034951B2 (ja) 2016-06-08 2022-03-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 操作されたウイルスベクターは炎症および免疫応答の誘導を低減する
US11370794B2 (en) 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
JP6886854B2 (ja) * 2017-04-13 2021-06-16 シスメックス株式会社 被検物質の情報取得方法
JP2021502381A (ja) 2017-11-08 2021-01-28 プレジデント アンド フェローズ オブ ハーバード カレッジ ウイルスベクター誘発性炎症反応を阻害するための組成物および方法
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
US11863189B2 (en) * 2021-03-05 2024-01-02 Taiwan Semiconductor Manufacturing Company, Ltd. Input buffer circuit
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US4587329A (en) * 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US6312679B1 (en) * 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
JP3012244B2 (ja) 1987-09-21 2000-02-21 ジェン―プローブ インコーポレイテッド ヌクレオチドプローブ用非ヌクレオチド連結試薬
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
ATE227342T1 (de) * 1993-09-02 2002-11-15 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
KR20000016414A (ko) 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US6489304B2 (en) * 1997-05-01 2002-12-03 Hybridon, Inc. Hyperstructure-forming carriers
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
US6080580A (en) * 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
CN1762990A (zh) 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2001068697A2 (en) 2000-03-17 2001-09-20 Gorczynski Reginald M Methods and compositions for immunoregulation
WO2002010438A2 (en) * 2000-07-28 2002-02-07 The Johns Hopkins University Serial analysis of transcript expression using long tags
JP4049357B2 (ja) 2000-08-11 2008-02-20 独立行政法人科学技術振興機構 ポルフィリン環が互いにメゾ−メゾ炭素結合と2つのβ−β炭素の結合との三つの結合により一方向に縮環したポルフィリン化合物およびその合成方法
EP1379264A4 (en) * 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
AU2003225495B2 (en) 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN100471486C (zh) * 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
DK1569696T3 (da) * 2002-11-21 2010-11-15 Bayhill Therapeutics Inc Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
JP5102959B2 (ja) 2002-12-23 2012-12-19 ダイナバックス テクノロジーズ コーポレイション 免疫刺激配列オリゴヌクレオチド及びその使用方法
US20070009899A1 (en) * 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
WO2005086835A2 (en) 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
JP2008514187A (ja) 2004-09-01 2008-05-08 ダイナバックス テクノロジーズ コーポレイション 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
CA2591582A1 (en) * 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
MX2008008279A (es) 2005-12-20 2009-03-04 Idera Pharmaceuticals Inc Actividad inmunoestimuladora de oligonucleotidos inmunoestimuladores palindromicos que contienen diferentes longitudes de segmentos palindromicos.
WO2007095387A2 (en) 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
KR101221589B1 (ko) 2006-04-07 2013-01-15 이데라 파마슈티칼즈, 인코포레이티드 Tlr7 및 tlr8에 대한 안정화된 면역 조절성 rna〔simra〕 화합물
EP2209896B1 (en) * 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity

Similar Documents

Publication Publication Date Title
JP2012191939A5 (enExample)
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
JP2015532097A5 (enExample)
JP2018507711A5 (enExample)
JP2016513976A5 (enExample)
JP2020522244A5 (enExample)
JP2016513460A5 (enExample)
JP2017505116A5 (enExample)
MX2015009006A (es) Oligonucleotidos inhibitorios y su uso en terapia.
JP2016530265A5 (enExample)
JP2018519944A5 (enExample)
Ghayour-Mobarhan et al. The potential role of heat shock proteins in cardiovascular disease: evidence from in vitro and in vivo studies
JP2016523943A5 (enExample)
박형신 et al. The Effects of Book-Making Activities with Music-Listening on Young Children" s Creativity and Character
石川千尋 Roles of serotonergic system during the postnatal period in the development of brain and behavior
배재영 et al. Main gene combinations and genotype identification of Hanwoo quality with SNPHarvester
TH189259S (th) ไม้แขวนเสื้อ
Andueza Site-specific sound installations in the urban environment
Egorov Buying addicition (compulsive shopping)
Kaleigh Joseph Conrad and imperialism
李然然 The association of olanzapine-induced metabolic disturbance related measures with TCF7L2 gene expression
Romagnani An update on allergic diseases
Kapran REALIZATION OF ORGANIZATIONALLY-PEDAGOGICAL TERMS OF PREPARATION OF FUTURE ORGANIZERS OF OFFICE WORK IS TO SELF-EDUCATION ACTIVITY IN HIGHER EDUCATIONAL ESTABLISHMENTS OF І-ІІ OF LEVELS OF ACCREDITATION
Ahangari et al. C46 OBESITY INFLUENCES ON THE LUNG: Chitotriosidase (chit1) Regulates Lung Inflammation And Obesity
Guoping et al. The Feeding and Breeding Management of Addax